Zynerba's ZYN002 meets in Phase II for fragile X

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) reported top-line data from the open-label Phase II FAB-C trial in 20 children ages 6-17 with fragile X syndrome showing that ZYN002 met the primary endpoint of reducing Anxiety, Depression and Mood Scale (ADAMS) total score at week 12 compared to baseline. Specifically, ZYN002 reduced the endpoint from a baseline score of 33.4 points to 18.1 points at week 12 (p<0.0001). Additionally, ZYN002 significantly improved the General Anxiety, Social Avoidance, Compulsive Behavior and Manic/Hyperactive Behavior subscales of ADAMS at week 12 compared to baseline.

Compared to baseline, ZYN002 also significantly improved all measures of the Aberrant Behavior Checklist for Fragile X (ABC-FXS), a secondary endpoint, including irritability, hyperactivity, inability to pay attention, social avoidance, repetitive movements and inappropriate speech. ZYN002 was well tolerated...